Pharmaceutical Contract Manufacturing Market CAGR To Reach 4.5% between 2025 and 2035, Driven by the Need to Reduce Manufacturing Costs and Speed Up Drug Delivery | Roots Analysis

According to our latest market report "Pharmaceutical Contract Manufacturing Market by Type of Product Manufactured, Type of API, API Potency, Type of FDF, Dosage Form, Type of Oral Solid, Type of Packaging Offered, Scale of Operation, End User, Geographical Regions and Key Players: Industry Trends and Global Forecasts, till 2035", the pharmaceutical contract manufacturing market is estimated to be USD 100.3 billion in 2025. It is expected to reach USD 155.4 billion by 2035, representing a CAGR of 4.5% between 2025 and 2035.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/pharmaceutical-contract-manufacturing-market-2nd-edition-2018-2028/request-quote.html

Contract manufacturing refers to the outsourcing of certain development and / or manufacturing services to a third-party service provider. This involves the production of goods by one company, under the label or brand of another company. Notably, commonly outsourced processes by pharma clients include formulation design, dosage form development, clinical / commercial production, packaging, and distribution. Interestingly, the modern pipeline of drug candidates is getting more complex, thus requiring specialized facilities, equipment, and operational expertise. The number of patients suffering from chronic diseases has also increased significantly, resulting in incessant demand for advanced medicines. In order to meet this growing demand, several small players and certain pharma giants, have begun outsourcing their manufacturing operations to contract service providers. Technological advances and market demand for novel therapeutics have continued to evolve. CMOs are navigating emerging trends, by including personalized therapeutics, continuous manufacturing processes, and digital health integration techniques. By embracing innovation, sustainability, and collaborative approaches, pharmaceutical CMOs will significantly contribute to the healthcare domain in the coming years.

Pharmaceutical Contract Manufacturing Market Segments
Based on the type of product manufactured, the market is segmented into APIs and Intermediates, and FDFs.

1. The APIs and intermediates sub-segment led the global pharmaceutical contract manufacturing market, capturing the largest revenue share of around 60% in the current year.
2. API and intermediates sub-segment is anticipated to show the highest growth rate of 4.5%, during the forecast period.

Based on the type of API, the market is segmented into originator APIs and generic APIs.

1. The originator APIs sub-segment led the global pharmaceutical contract manufacturing market, capturing the largest revenue share of more than 50% in the current year.
2. The generic APIs sub-segment is anticipated to grow at an annualized rate of 5.0%, during the forecast period.

Based on the API potency, the market is segmented into low potent APIs and high potent APIs.

1. The low potent APIs sub-segment led the global pharmaceutical contract manufacturing market, capturing the largest revenue share of around 85% in the current year.
2. The high potent APIs sub-segment is anticipated to grow at an annualized rate of 9.0%, during the forecast period.

Based on the type of FDF, the market is segmented into originator FDFs and generic FDFs.

1. The originator FDFs sub-segment led the global pharmaceutical contract manufacturing market, capturing the largest revenue share of about 55% in the current year.
2. The generic FDFs sub-segment is anticipated to grow at an annualized rate of 5.3%, during the forecast period.

Based on the dosage form, the market is segmented into oral solids, liquids, emulsions and other dosage forms.

1. The oral solids sub-segment led the global pharmaceutical contract manufacturing market, capturing the largest revenue share of around 55% in the current year.
2. The liquids sub-segment is anticipated to grow at an annualized rate of 4.5%, during the forecast period.

Based on the type of oral solid, the market is segmented into tablets, capsules and other oral solids.

1. The tablets sub segment is expected to hold the majority share of global pharmaceutical contract manufacturing market, capturing ~70% revenue share in the current year.
2. The capsules sub-segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 5.7% during the forecast period.

Based on the type of packaging offered, the market is segmented into bottles, blister packs, oral
liquid bottles, vials, prefilled syringes, cartridges, ampoules and other types of packaging.

1. The bottles sub segment is expected to hold the majority share of global pharmaceutical contract manufacturing market, capturing about 30% revenue share in the current year.
2. The blister packs sub-segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 5.5% during the forecast period.

Based on the scale of operation, the market is segmented into clinical scale and commercial scale.

1. The commercial scale sub segment is expected to hold the majority share of global pharmaceutical contract manufacturing market, capturing about 95% of revenue share in the current year.
2. The clinical scale sub-segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 7.8% during the forecast period.

Based on the end user, the market is segmented into small companies, mid-sized companies, and
large and very large companies.

1. The large and very large companies sub segment is expected to hold the majority share of global pharmaceutical contract manufacturing market, capturing around 45% revenue share in the current year.
2. The small companies sub-segment is anticipated to be the fastest growing segment in this industry, with an annualized rate of 5.2% during the forecast period.

Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa.

1. North America dominated the global pharmaceutical contract manufacturing market and accounted for the largest revenue share (~45%) in the current year.
2. In Asia-Pacific, the global pharmaceutical contract manufacturing market is anticipated to demonstrate lucrative growth of 5.2% during the forecast period.

Pharmaceutical Contract Manufacturing Market Regional Outlook
Based on the geographical regions, the pharmaceutical contract manufacturing market can be segmented into three major regions, including North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa. Led by the US, North America is anticipated to capture the majority share of the pharmaceutical contract manufacturing market in 2025, and this trend is likely to remain unchanged during the forecast period. This can be attributed to well-established pharmaceutical contract manufacturing industry, along with robust infrastructure and significant investments in research and development of manufacturing technologies within this region.

To request a sample copy / brochure of this report, please visit:
https://www.rootsanalysis.com/reports/pharmaceutical-contract-manufacturing-market-2nd-edition-2018-2028/request-sample.html

Key Report Takeaways
1. The current market landscape features the presence of close to 510 players that claim to offer contract manufacturing services for pharmaceuticals across the world; 50% of these are headquartered in Asia-Pacific
2. Majority (~90%) of the pharmaceutical contract manufacturers offer services for producing finished dose formulations; further, >75% players offer services for fill finish / packaging and labeling
3. M&As allow companies to establish themselves as one-stop shops and build a competitive edge in the steadily evolving market landscape
4. In order to meet the rising demand for small molecules, CMOs have made significant investments in expanding their existing capacities and capabilities; in the recent past, this trend was most pronounced in Europe
5. The global pharmaceutical contract manufacturing capacity is well distributed across different facilities worldwide; notably, large and very large players account for more than 85% of the total capacity
6. In order to reduce high capital investments and operational costs associated with setting up and maintaining an in-house production facility, the demand for pharmaceutical contract manufacturing is anticipated to rise significantly
7. Owing to the enhanced cost efficiency and flexibility offered by CMOs, a relatively larger proportion of drug developers are outsourcing their manufacturing operations, driving the growth of this market
8. Currently, majority of the pharmaceutical contract manufacturing market share is captured by North America; this can be attributed to the advanced healthcare infrastructure, enabling players to conduct extensive research
9. The oral solids sub-segment is estimated to capture majority of the overall market share in the current year, owing to their cost-efficiency, ease of administration and high patient compliance

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/pharmaceutical-contract-manufacturing-market/191.html#overview

Pharmaceutical Contract Manufacturing Market Key Players
Examples of key companies engaged in pharmaceutical contract manufacturing market (which have also been profiled in this market report; the complete list of companies is available in the full report) include Albemarle, Aspen Pharmacare, Bausch Health Sciences, Catalent, Delpharm, Eurofins Scientific, Evonik Industries, Fareva, Fresenius Kabi, Intas Pharmaceuticals, Lonza, Micro Labs, Nipro Patch, Patheon, PiSA Farmacéutica, Recipharm, Sandoz, West Pharmaceutical Services, Wockhardt and WuXi AppTec.

Contact Details for Roots Analysis
Chief Executive: Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com
Website: https://www.rootsanalysis.com/

About Roots Analysis
Roots Analysis is a global leader in the market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.